Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Enlivex ( (ENLV) ) has issued an update.
On April 21, 2025, Enlivex Therapeutics announced the completion of patient enrollment in the Phase II stage of its Phase I/II trial for Allocetra™ in treating moderate to severe knee osteoarthritis. This milestone follows promising initial efficacy data from the Phase I stage, with the company expecting to release topline data by August 2025. The trial aims to evaluate the safety and efficacy of Allocetra™ in improving joint pain and function, potentially transforming osteoarthritis treatment and impacting the significant patient population affected by this condition.
Spark’s Take on ENLV Stock
According to Spark, TipRanks’ AI Analyst, ENLV is a Underperform.
Enlivex’s financial challenges, characterized by no revenue and ongoing cash burn, significantly impact its stock score. Technical indicators show neutral momentum, but the negative valuation metrics reflect ongoing financial difficulties. The absence of positive corporate events or earnings call data limits the potential for a higher score.
To see Spark’s full report on ENLV stock, click here.
More about Enlivex
Enlivex Therapeutics Ltd. is a clinical-stage company specializing in macrophage reprogramming immunotherapy. The company is developing Allocetra™, a universal, off-the-shelf cell therapy aimed at reprogramming macrophages into their homeostatic state to address life-threatening and debilitating conditions.
YTD Price Performance: -30.65%
Average Trading Volume: 128,073
Technical Sentiment Signal: Buy
Current Market Cap: $18.91M
For an in-depth examination of ENLV stock, go to TipRanks’ Stock Analysis page.